Celltrion Reveals Follow-up Clinical Results of Avastin Biosimilar at ESMO

[Asia Economy Reporter Chunhee Lee] The Celltrion Group announced on the 12th that it participated in the European Society for Medical Oncology (ESMO Congress 2022) held in Paris, France, to promote the competitiveness of its anti-cancer antibody biosimilars such as 'Vegzelma (generic name Bevacizumab, development code CT-P16)'.

ESMO, held from the 9th to the 13th, is Europe's largest and most prestigious cancer conference. This year, it was conducted both on-site in France and online simultaneously. At this ESMO, Celltrion plans to publicly present the follow-up results of the Phase 3 clinical trial of Vegzelma on the 12th in poster form at the conference venue. Celltrion's overseas sales and marketing arm, Celltrion Healthcare, also opened a dedicated promotional booth to introduce the competitiveness of Celltrion's developed anti-cancer antibody biosimilars, including Vegzelma (Avastin biosimilar), the hematologic cancer treatment drug Truxima (MabThera biosimilar), and the breast and gastric cancer treatment drug Herzuma (Herceptin biosimilar).

The Celltrion Group plans to launch Vegzelma in the European market in the second half of this year, following Truxima and Herzuma. Vegzelma is the third anti-cancer antibody biosimilar for which Celltrion has obtained global approval. In August, it received marketing authorization from the European Commission (EC) for all indications (Full Label) approved for Avastin, including metastatic colorectal cancer and non-small cell lung cancer. Subsequently, Celltrion has applied for marketing authorization for Vegzelma from the Korean Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA), expecting approval within this year.

According to pharmaceutical market research firm IQVIA and Celltrion Healthcare, Truxima recorded a 26.5% market share and Herzuma 12.6% in the European market in the first quarter of this year, steadily establishing their presence in Europe. With the launch of Vegzelma in the second half of this year, Celltrion plans to further strengthen its competitiveness in the anti-cancer drug sector within the European market. To facilitate the rapid market entry of Vegzelma, Celltrion has also completed a patent agreement with Roche, the original drug developer, for global market launch, aiming for an early launch targeting the entire indication market.

A Celltrion Group official said, “At ESMO, one of the world's top three cancer conferences, we introduced the global competitiveness of Celltrion Group's anti-cancer antibody biosimilars and publicly presented the follow-up results of Vegzelma's Phase 3 clinical trial in poster form. We will do our best to ensure that Vegzelma, scheduled for launch in the second half of the year, settles early in the European market and that the remaining global approvals proceed smoothly.”

This content was produced with the assistance of AI translation services.